2 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 2 Not applicable, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Heart Failure, Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure, Reduced Ejection Fraction trials Research Report on Heart Failure, Reduced Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Does the Sequence of Heart Failure Medication Matter up front use of mineralocorticoid receptor antagonist - Heart Failure, Reduced Ejection Fraction | Not applicable | Not yet recruiting | Aarhus University Hospital | 16000 | 2025-02-01 | 2024-10-15 |
| Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes Ketone Monoester (KE) - Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction | Early Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 10 | 2024-01-16 | 2026-01-21 |
| Heart Failure With Reduced Ejection Fraction: Adjuvant Therapy With Neurostimulation and Chlorella Pyrenoidosa (HD-tDCS) Chlorella pyrenoidosa, High Definition Transcranial Direct Current Stimulation - Heart Failure, Reduced Ejection Fraction, Vitamin B12 Deficiency | Not applicable | Unknown | Federal University of Paraíba | 28 | 2023-09-26 | 2024-07-30 |
| The Impact of Ivabradine on Left Ventricular Reverse Remodeling in Nonischemic Dilated Cardiomyopathy (NIDCM) on Current Medical Therapy Era Dilated Cardiomyopathy, Ventricular Remodeling | Unknown | Yonsei University | 500 | 2023-07-15 | 2023-08-03 | |
| Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice Dapagliflozin - Heart Failure, Reduced Ejection Fraction | Completed | AstraZeneca | 252 | 2022-04-19 | 2025-03-28 | |
| Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients. sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696) - Heart Failure, Reduced Ejection Fraction | Phase 4 | Completed | Novartis Pharmaceuticals | 140 | 2016-12-16 | 2021-10-07 |
Heart Failure, Systolic (6) · Heart Failure (2) · Cardiomyopathy, Dilated (1) · Diabetes Mellitus, Type 2 (1) · Dilatation, Pathologic (1) · Hypertrophy, Left Ventricular (1) · Motor Activity (1) · Ventricular Remodeling (1) · Vitamin B 12 Deficiency (1)
Cardiovascular Diseases (6) · Heart Diseases (6) · Heart Failure (4) · Cardiomegaly (2) · Nutritional and Metabolic Diseases (2) · Pathological Conditions, Anatomical (2) · Pathological Conditions, Signs and Symptoms (2) · Avitaminosis (1) · Behavior (1) · Cardiomyopathies (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Deficiency Diseases (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1)
Enalapril (1) · Valsartan (1) · dapagliflozin (1) · rVSV-deltaG-spike COVID-19 vaccine (1) · sacubitril (1) · sacubitril and valsartan sodium hydrate drug combination (1)
Aarhus University Hospital (1) · AstraZeneca (1) · Federal University of Paraíba (1) · Novartis Pharmaceuticals (1) · The University of Texas Health Science Center at San Antonio (1) · Yonsei University (1)
United States (2) · Brazil (1) · Italy (1) · South Korea (1)
Andrea Di Lenarda, MD (1) · Andrea Mortara, MD (1) · Andrea Ungar, MD (1) · Carolina Solis-Herrera, MD (1) · Ciro Indolfi, MD (1) · Marco Metra, MD (1) · Massimo Iacoviello, MD (1) · Massimo Volpe, MD (1) · Maurizio Volterrani, MD (1) · Pasquale Perrone Filardi, MD (1) · Pietro Ameri, MD (1) · Seok-Min Kang (1) · Stefano Carugo, MD (1) · Vanessa M Cintra, Msc (1)
1UM1TR004538-01 (1)